pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Rare Disease · news · pharmadog
← back to Rare Disease
News · Rare Disease
846
stories
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Sep 1, 26
As MAHA champions nutrition, it’s ignoring the experts, dietitians say
stat
Aug 31, 26
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
biopharma dive
Aug 31, 26
STAT+: Trump strikes nine more deals with drugmakers to lower prices
stat
Aug 31, 26
FDA OKs Takeda, Protagonist drug for rare blood cancer
biopharma dive
Aug 31, 26
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
biospace
Aug 31, 26
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
biopharma dive
Aug 31, 26
Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split
biospace
Aug 31, 26
STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and more
stat
Aug 31, 26
STAT+: Can a pregnancy hormone steer a cardiovascular treatment?
stat
Aug 31, 26
Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
biospace
Aug 31, 26
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
fiercebiotech
Aug 31, 26
STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy
stat
Aug 31, 26
STAT+: After a rough stretch, mRNA gets a boost — at least for now
stat
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 31, 26
China poses increasing security risk as US biotech innovation edge erodes
biospace
Aug 31, 26
Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88B
raps
Aug 30, 26
STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
stat
Aug 30, 26
STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
stat
Aug 28, 26
FDA approves Takeda, Protagonist drug for rare blood disorder
endpoints
Aug 28, 26
FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder
fda press
Aug 28, 26
Everything Sprouts, LLC Expands Voluntarily Recall to Include Robust Radish Mix Due to Potential E. Coli and Salmonella Risk
fda recalls
Aug 28, 26
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
biospace
Aug 28, 26
Panorama Produce Recalls Mangoes Due to Possible Salmonella Contamination
fda recalls
Aug 28, 26
STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
stat
Aug 28, 26
Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro
biospace
Aug 28, 26
FDA green lights Priovant drug for rare skin disease
biopharma dive
Aug 28, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and more
stat
Aug 28, 26
Priovant nabs first FDA approval for targeted tablet in dermatomyositis
biospace
Aug 28, 26
STAT+: Cytokinetics details trial win for what could be its next approval
stat
← prev
page 9 of 29
next →
